CpG-Induced IFNγ expands TLR4-specific IL-18 responses in vivo

Sameer Gupta; Meetha P. Gould; Jennifer DeVecchio; David H. Canaday; Jeffery J. Auletta; Frederick P. Heinzel

doi:10.1016/j.cellimm.2006.12.004

CpG-Induced IFNγ expands TLR4-specific IL-18 responses in vivo

Sameer Gupta, Meetha P. Gould, Jennifer DeVecchio, David H. Canaday, Jeffery J. Auletta, Frederick P. Heinzel

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Serum IL-18 responses to LPS increase after pretreatment with CpG-containing DNA. Compared to saline-pretreated controls, mice pretreated with CpG for two days produced 20-fold more serum IL-18 when challenged with lipopolysaccharide (LPS). In contrast, IFNγ-deficiency or anti-IFNγ pretreatment reduced CpG-expanded IL-18 responses to LPS by 67 and 83%, respectively. Mice pretreated with either IFNγ or CpG comparably increased LPS-inducible serum IL-18 responses. LPS, compared to challenge with other TLR agonists, was best able to trigger high serum IL-18 levels in CpG-pretreated mice and this response was TLR4-dependent. CpG, compared to pretreatment with other TLR agonists, optimally expanded LPS-induced IL-18 responses that correlated with higher levels of circulating IFNγ levels prior to LPS challenge. High-level serum IL-18 responses were caspase-1-dependent and P2X7 receptor-independent. We conclude that CpG promotes high-level IL-18 synthesis by an IFNγ-dependent and IFNγ-sufficient mechanism in vivo that is optimally triggered by LPS.

Original language	English (US)
Pages (from-to)	75-82
Number of pages	8
Journal	Cellular Immunology
Volume	243
Issue number	2
DOIs	https://doi.org/10.1016/j.cellimm.2006.12.004
State	Published - Oct 2006
Externally published	Yes

Bibliographical note

Funding Information:
Fred Heinzel is supported by the VA Medical Research Service and by NIH Grant AI45602, Jeff Auletta by AI57801 and Sameer Gupta by T32 HL07889. We thank Drs. Eric Pearlman, George Dubyak and Michelle Lin for discussion, encouragement and sharing of reagents in these studies.

Keywords

Interferon, type II
Interleukin-18
Mice
Purinergic P2
Receptors
Toll-like receptor 9

Publisher link

10.1016/j.cellimm.2006.12.004

Find It

Find It at U of M Libraries

Cite this

@article{03c26e96c64d46b3af1cb84e181725ab,

title = "CpG-Induced IFNγ expands TLR4-specific IL-18 responses in vivo",

abstract = "Serum IL-18 responses to LPS increase after pretreatment with CpG-containing DNA. Compared to saline-pretreated controls, mice pretreated with CpG for two days produced 20-fold more serum IL-18 when challenged with lipopolysaccharide (LPS). In contrast, IFNγ-deficiency or anti-IFNγ pretreatment reduced CpG-expanded IL-18 responses to LPS by 67 and 83\%, respectively. Mice pretreated with either IFNγ or CpG comparably increased LPS-inducible serum IL-18 responses. LPS, compared to challenge with other TLR agonists, was best able to trigger high serum IL-18 levels in CpG-pretreated mice and this response was TLR4-dependent. CpG, compared to pretreatment with other TLR agonists, optimally expanded LPS-induced IL-18 responses that correlated with higher levels of circulating IFNγ levels prior to LPS challenge. High-level serum IL-18 responses were caspase-1-dependent and P2X7 receptor-independent. We conclude that CpG promotes high-level IL-18 synthesis by an IFNγ-dependent and IFNγ-sufficient mechanism in vivo that is optimally triggered by LPS.",

keywords = "Interferon, type II, Interleukin-18, Mice, Purinergic P2, Receptors, Toll-like receptor 9",

author = "Sameer Gupta and Gould, \{Meetha P.\} and Jennifer DeVecchio and Canaday, \{David H.\} and Auletta, \{Jeffery J.\} and Heinzel, \{Frederick P.\}",

note = "Funding Information: Fred Heinzel is supported by the VA Medical Research Service and by NIH Grant AI45602, Jeff Auletta by AI57801 and Sameer Gupta by T32 HL07889. We thank Drs. Eric Pearlman, George Dubyak and Michelle Lin for discussion, encouragement and sharing of reagents in these studies.",

year = "2006",

month = oct,

doi = "10.1016/j.cellimm.2006.12.004",

language = "English (US)",

volume = "243",

pages = "75--82",

journal = "Cellular Immunology",

issn = "0008-8749",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - CpG-Induced IFNγ expands TLR4-specific IL-18 responses in vivo

AU - Gupta, Sameer

AU - Gould, Meetha P.

AU - DeVecchio, Jennifer

AU - Canaday, David H.

AU - Auletta, Jeffery J.

AU - Heinzel, Frederick P.

N1 - Funding Information: Fred Heinzel is supported by the VA Medical Research Service and by NIH Grant AI45602, Jeff Auletta by AI57801 and Sameer Gupta by T32 HL07889. We thank Drs. Eric Pearlman, George Dubyak and Michelle Lin for discussion, encouragement and sharing of reagents in these studies.

PY - 2006/10

Y1 - 2006/10

N2 - Serum IL-18 responses to LPS increase after pretreatment with CpG-containing DNA. Compared to saline-pretreated controls, mice pretreated with CpG for two days produced 20-fold more serum IL-18 when challenged with lipopolysaccharide (LPS). In contrast, IFNγ-deficiency or anti-IFNγ pretreatment reduced CpG-expanded IL-18 responses to LPS by 67 and 83%, respectively. Mice pretreated with either IFNγ or CpG comparably increased LPS-inducible serum IL-18 responses. LPS, compared to challenge with other TLR agonists, was best able to trigger high serum IL-18 levels in CpG-pretreated mice and this response was TLR4-dependent. CpG, compared to pretreatment with other TLR agonists, optimally expanded LPS-induced IL-18 responses that correlated with higher levels of circulating IFNγ levels prior to LPS challenge. High-level serum IL-18 responses were caspase-1-dependent and P2X7 receptor-independent. We conclude that CpG promotes high-level IL-18 synthesis by an IFNγ-dependent and IFNγ-sufficient mechanism in vivo that is optimally triggered by LPS.

AB - Serum IL-18 responses to LPS increase after pretreatment with CpG-containing DNA. Compared to saline-pretreated controls, mice pretreated with CpG for two days produced 20-fold more serum IL-18 when challenged with lipopolysaccharide (LPS). In contrast, IFNγ-deficiency or anti-IFNγ pretreatment reduced CpG-expanded IL-18 responses to LPS by 67 and 83%, respectively. Mice pretreated with either IFNγ or CpG comparably increased LPS-inducible serum IL-18 responses. LPS, compared to challenge with other TLR agonists, was best able to trigger high serum IL-18 levels in CpG-pretreated mice and this response was TLR4-dependent. CpG, compared to pretreatment with other TLR agonists, optimally expanded LPS-induced IL-18 responses that correlated with higher levels of circulating IFNγ levels prior to LPS challenge. High-level serum IL-18 responses were caspase-1-dependent and P2X7 receptor-independent. We conclude that CpG promotes high-level IL-18 synthesis by an IFNγ-dependent and IFNγ-sufficient mechanism in vivo that is optimally triggered by LPS.

KW - Interferon, type II

KW - Interleukin-18

KW - Mice

KW - Purinergic P2

KW - Receptors

KW - Toll-like receptor 9

UR - https://www.scopus.com/pages/publications/33947228402

UR - https://www.scopus.com/inward/citedby.url?scp=33947228402&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2006.12.004

DO - 10.1016/j.cellimm.2006.12.004

M3 - Article

C2 - 17292338

AN - SCOPUS:33947228402

SN - 0008-8749

VL - 243

SP - 75

EP - 82

JO - Cellular Immunology

JF - Cellular Immunology

IS - 2

ER -

CpG-Induced IFNγ expands TLR4-specific IL-18 responses in vivo

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this